New therapies for heart failure.
Riggs
Janet M
JM
Department of Cardiology, University of Pennsylvania Medical Center-Presbyterian, Philadelphia, USA.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000077545:Eplerenone; D006333:Heart Failure / Q000145:classification / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D006835:Hydrazones / Q000627:therapeutic use; D045283:Natriuretic Agents / Q000627:therapeutic use; D020097:Natriuretic Peptide, Brain / Q000627:therapeutic use; D018377:Neurotransmitter Agents / Q000502:physiology; D011724:Pyridazines / Q000627:therapeutic use; D000077464:Simendan; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D004232:Diuretics; D006835:Hydrazones; D045283:Natriuretic Agents; D018377:Neurotransmitter Agents; D011724:Pyridazines; D020097:Natriuretic Peptide, Brain; D013148:Spironolactone; D000077464:Simendan; D000077545:Eplerenone